The FDA's attempts to expedite drug approval may have undermined safety, an article in the...
The FDA's attempts to expedite drug approval may have undermined safety, an article in the Journal of the American Medical Association says. The authors, Thomas Moore and Curt Furberg, point to problems with Novartis' (NVS) Gilenya drug for multiple sclerosis, AstraZeneca's (AZN) Caprelsa for thyroid cancer and Boehringer Ingelheim's Pradaxa for stroke prevention.
From other sites
at Zacks.com (Mar 23, 2015)
at Zacks.com (Mar 18, 2015)
at MarketWatch.com (Mar 6, 2015)
at Zacks.com (Mar 5, 2015)
at Nasdaq.com (Feb 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs